Guideline: IVIg effective for certain nerve and muscle disorders

March 26, 2012

Intravenous immune globulin (IVIg) is an effective treatment for certain disorders of the nerve and muscles, including Guillain-Barré syndrome (GBS) and a form of neuropathy called chronic inflammatory demyelinating polyneuropathy (CIDP), according to a guideline issued by the American Academy of Neurology. The guideline is published in the March 27, 2012, print issue of Neurology, the medical journal of the American Academy of Neurology.

IVIg is a type of immunotherapy that fights the misdirected immune system. It is not well understood exactly how IVIg works, but it likely regulates an overactive immune system. Immune globulin is a protein in human blood that likely links itself with antibodies or other substances directed at the .

According to the guideline, strong evidence shows that IVIg effectively treats Guillain-Barré syndrome, a rare disorder in which the body's attacks the peripheral nervous system, causing tingling and weakness in the arms and legs. The evidence shows that IVIg works as well as the treatment called plasma exchange to treat GBS.

Strong evidence also shows that long-term use of IVIg can help treat CIDP, which is the chronic counterpart of GBS and can affect nerves in the arms and legs and other parts of the body.

"Serious side effects are rare with IVIg, but there is a risk of kidney failure and a condition that causes the blood to be more likely to form clots," said guideline lead author Huned S. Patwa, MD, of Yale University and the VA Connecticut Healthcare System in West Haven and a member of the American Academy of . "It is important to work with your doctor when deciding whether to use IVIg for a neuromuscular disorder."

The guideline also found that IVIg is effective in helping to treat moderate to severe forms of myasthenia gravis and a rare condition known as multifocal motor neuropathy. It may also be helpful in treating neuromuscular disorders known as nonresponsive dermatomyositis and Lambert-Eaton myasthenic syndrome.

Explore further: Better and more affordable treatments for sufferers of autoimmune diseases

Related Stories

Costly treatment 'ineffective for babies'

September 30, 2011

(Medical Xpress) -- A worldwide study involving University of Sydney researchers has concluded that a costly and controversial treatment for neonatal sepsis is ineffective.

Recommended for you

Scientists identify neurons devoted to social memory

September 30, 2016

Mice have brain cells that are dedicated to storing memories of other mice, according to a new study from MIT neuroscientists. These cells, found in a region of the hippocampus known as the ventral CA1, store "social memories" ...

Throwing light on the brain's perception of transparency

September 30, 2016

Researchers have created a new optical illusion that helps reveal how our brains determine the material properties of objects – such as whether they are transparent, shiny, matte or translucent – just from looking at ...

Scientists track unexpected mechanisms of memory

September 29, 2016

Do you remember Simone Biles's epic gymnastics floor routine that earned her a fifth Olympic medal? Our brains hold on to memories like these via physical changes in synapses, the tiny connections between neurons.

Some brains are blind to moving objects

September 28, 2016

As many as half of people are blind to motion in some part of their field of vision, but the deficit doesn't have anything to do with the eyes.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.